The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) given to adolescents with obesity was associated with a one-third ...

We recently compiled a list of the 10 Most Promising Future Stocks According to Analysts. In this article, we are going to ...

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...

Novo Nordisk NVO has outperformed the market over the past 10 years by 6.26% on an annualized basis producing an average ...

A s a teen, Lecritia Roberts injected herself with insulin using a glass vial and a syringe to manage her type 1 diabetes, ...

Recent data reveals that the eurozone economy has narrowly skirted a recession, showing lukewarm yet positive growth. With ...

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

The UK Government is considering using weight-loss drugs to help support obese people in returning to work and reduce the high rates of long-term sickness, which have become a significant strain on ...

"Additionally, GLP-1 agonists can cause gastrointestinal side effects like nausea, vomiting, and diarrhoea. These symptoms ...

Scientists have designed a new form of insulin that can automatically switch itself on and off depending on glucose levels in ...

Eighty states, cities, counties, school boards and unions have joined litigation in a New Jersey district court against the three major pharmacy middlemen.